These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32185399)

  • 1. Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy.
    Schnell A; Schwarz B; Wahlbuhl M; Allabauer I; Hess M; Weber S; Werner F; Schmidt H; Rechenauer T; Siebenlist G; Kaspar S; Ehrsam C; Rieger D; Rückel A; Metzler M; Christoph J; Woelfle J; Rascher W; Hoerning A
    Inflamm Bowel Dis; 2021 Jan; 27(2):224-235. PubMed ID: 32185399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced CD27
    Pararasa C; Zhang N; Tull TJ; Chong MHA; Siu JHY; Guesdon W; Chavele KM; Sanderson JD; Langmead L; Kok K; Spencer J; Vossenkamper A
    Front Immunol; 2019; 10():361. PubMed ID: 30891036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
    Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
    Buhl S; Dorn-Rasmussen M; Brynskov J; Ainsworth MA; Bendtzen K; Klausen PH; Bolstad N; Warren DJ; Steenholdt C
    Scand J Gastroenterol; 2020 Aug; 55(8):884-890. PubMed ID: 32631131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.
    Bravo F; Macpherson JA; Slack E; Patuto N; Cahenzli J; McCoy KD; Macpherson AJ; Juillerat P;
    Clin Transl Gastroenterol; 2021 Feb; 12(2):e00298. PubMed ID: 33735154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Lee JH; Choe YH
    Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY; Lee Y; Choe BH; Kang B
    Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Choe YH
    Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.